María Rosario Chica-Parrado, Gun Min Kim, Yasuaki Uemoto, Fabiana Napolitano, Chang-Ching Lin, Dan Ye, Emmanuel Bikorimana, Yisheng Fang, Kyung-Min Lee, Saurabh Mendiratta, Ariella B Hanker, Carlos L Arteaga
Luminal Androgen Receptor (LAR) triple-negative breast cancers (TNBC) express androgen receptors (AR), exhibit high frequency of PIK3CA mutations and intact RB. Herein, we investigated combined blockade of the CDK4/6 and PI3K signaling with palbociclib, alpelisib, and capivasertib, which inhibit CDK4/6, PI3Kα, and AKT1-3, respectively. The combination of palbociclib/capivasertib, but not palbociclib/alpelisib, synergistically inhibited proliferation of MDA-MB-453 and MFM-223 LAR cells [synergy score 7...
September 5, 2024: Cancer Letters